Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results
12 mai 2022 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022 First patient dosed in Phase 2a trial evaluating tegoprubart in IgA Nephropathy with...
Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
09 mai 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
05 mai 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals to Participate in LifeSci Partners Immunology & Inflammation Symposium
03 mai 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference
18 avr. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon to Host Virtual R&D Day on Thursday, April 28, 2022
14 avr. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
24 mars 2022 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing clinical studies evaluating tegoprubart in kidney transplantation, IgA nephropathy, and islet cell transplantation...
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
17 mars 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook
14 févr. 2022 08h00 HE
|
Eledon Pharmaceuticals, Inc.
Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart (AT-1501) in Amyotrophic Lateral Sclerosis (ALS) Announces USAN Approval of Generic Name “tegoprubart” for lead...
Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference
08 févr. 2022 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...